STING agonist treatment significantly enhanced levels of the degranulation marker CD107a in the NK cells (Fig. 5B) and suggests NK-cell cytotoxicity against HNSCC cells is greater with STING activation. Here, STING1 is linked to head and neck squamous cell carcinoma.